Due to some tantalizing hints of correlations between clinical responses and high PD-L1 expression on TC and/or tumor infiltrating IC [7, 8, 11–13], many research groups have opted to study PD-L1 expression on clinical or preclinical NSCLC samples. The gene discussed is CD274; the disease is neoplasm.